


PHARMACEUTICAL 2023



Aerovate Therapeutics Inc. Rank 67 of 446





PHARMACEUTICAL 2023





Aerovate Therapeutics Inc. Rank 67 of 446

The relative strengths and weaknesses of Aerovate Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aerovate Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 94% points. The greatest weakness of Aerovate Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 17% points.

The company's Economic Capital Ratio, given in the ranking table, is 231%, being 188% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	131,496
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,782
Liabilities, Non-Current	705
Other Assets	3,563
Other Compr. Net Income	-407
Other Expenses	25
Other Liabilities	71
Other Net Income	1,751
Other Revenues	0
Property and Equipment	242
Research and Development	38,622
Selling, General and Administrative Expense	14,615

Output Variable	Value in 1000 USD
Assets	135,301
Liabilities	8,558
Expenses	53,262
Revenues	0
Stockholders Equity	126,743
Net Income	-51,511
Comprehensive Net Income	-51,714
Economic Capital Ratio	231%